TABLE 1.
Comparison between the two cohorts of patients treated with chemoradiation and SBRT
| Variable | Value | CRT | SBRT | P |
|---|---|---|---|---|
| Age (y) | Median (range) | 67 (36‐89) | 67 (36‐83) | |
| ≤65 | 17 (42.5) | 17 (42.5) | .589 | |
| >65 | 23 (57.5) | 23 (57.5) | ||
| Gender | Male | 24 (60.0) | 27 (67.5) | .321 |
| Female | 16 (40.0) | 13(32.5) | ||
| ECOG PS | 0 | 22 (55.0) | 20 (50.0) | .493 |
| 1 | 16 (40.0) | 15 (37.5) | ||
| 2 | 2 (5.0) | 5 (12.5) | ||
| Tumor site | Head | 28 (70.0) | 24 (60.0) | .638 |
| Body | 10 (25.0) | 13 (32.5) | ||
| Tail | 2 (5.0) | 3 (7.5) | ||
| Tumor diameter (cm) | Median (range) | 4.0 (1.2‐8.7) | 4.0 (2.0‐7.0) | |
| <3.0 | 5 (12.5) | 5 (12.5) | .631 | |
| ≥3.0 and <3.9 | 18 (32.5) | 18 (32.5) | ||
| ≥3.9 | 22 (55.0) | 22 (55.0) | ||
| cT stage | 3 | 11 (27.5) | 11 (27.5) | .599 |
| 4 | 29 (72.5) | 29 (72.5) | ||
| cN stage | 0 | 22 (55.0) | 22 (55.0) | .589 |
| 1 | 18 (45.0) | 18 (45.0) | ||
| Biliary stent | No | 15 (37.5) | 19 (47.5) | .078 |
| Yes | 23 (57.5) | 13 (32.5) | ||
| Unknown | 2 (5.0) | 8 (20.0) | ||
| Neoadjuvant chemotherapy | No | 16 (40.0) | 16 (40.0) | .590 |
| Yes | 24 (60.0) | 24 (60.0) | ||
| Neoadjuvant chemotherapy regimen | Gemcitabine | 8 (33.3) | 3 (12.5) | .002* |
| Folfox | 1 (4.2) | 1 (4.2) | ||
| Folfirinox | 2 (8.3) | 6 (25.0) | ||
| Gemcitabine + Nab‐placlitaxel | 0 (0.0) | 9 (37.5) | ||
| Gemcitabine + Oxaliplatinum | 13 (54.2) | 5 (20.8) | ||
| Adjuvant chemotherapy | No | 31 (77.5) | 31 (77.5) | .605 |
| Yes | 9 (22.5) | 9 (22.5) | ||
| Adjuvant chemotherapy regimen | Gemcitabine | 7 (77.8) | 2 (22.2) | .073 |
| 5‐Fluorouracil | 0 (0.0) | 1 (11.1) | ||
| Folfirinox | 1 (11.1) | 4 (44.4) | ||
| Gemcitabine + Nab‐placlitaxel | 0 (0.0) | 2 (22.2) | ||
| Gemcitabine + Oxaliplatinum | 1 (11.1) | 0 (0.0) | ||
| Acute gastrointestinal toxicity | 0 | 24 (60.0) | 31 (77.5) | .175 |
| 1 | 12 (30.0) | 8 (20.0) | ||
| 2 | 4 (10.0) | 1 (2.5) | ||
| Late gastrointestinal toxicity | 0 | 35 (92.1) | 39 (97.5) | .244 |
| 1 | 1 (2.6) | 0 (0.0) | ||
| 2 | 2 (5.3) | 0 (0.0) | ||
| 3 | 0 (0.0) | 1 (2.5) |
Abbreviation: CHT, chemotherapy; CRT, chemoradiotherapy; ECOG PS, Eastern Cooperative Oncology Group performance status; SBRT, stereotactic body radiotherapy.
*
Significant P value.